The ACADEMIC study in perspective (azithromycin in coronary artery disease: Elimination of myocardial infection with chlamydia)

Journal of Infectious Diseases

Volumn 181, Issue 6 SUPPL. 3, 2000, Pages

  Anderson, Jeffrey L ^a,b   Muhlestein, Joseph B ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; C REACTIVE PROTEIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; UNSTABLE ANGINA PECTORIS;

EID: 0034088902     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315635     Document Type: Conference Paper

References (15)

1. 1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340: 115-26.
2. 2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-97.
3. 3. Morrow DA, Ridker PM. Inflammation in cardiovascular disease. In: Topol EJ, ed. Textbook of cardiovascular medicine. updates. Vol 2, no 4. Philadelphia: Lippincott-Raven Press, 1998 (1999 update).
4. 4. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis. Circulation 1997;96:4095-103.
5. 5. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167:841-9.
6. 6. Muhlestein JB, Hammon EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996;27:1555-61.
7. 7. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis: the Chlamydia pneumoniael Atherosclerosis Study Group. Ann Intern Med 1996;125:979-82.
8. 8. Fong IW, Chiu B, Vira E, Fong MW, Jang D, Mahoney J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997;35:48-52.
9. 9. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-6.
10. 10. Gupta S, Leatharn EW, Carrington M, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404-7.
11. 11. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for ROXIS study group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
12. 12. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99:1540-7.
13. 13. Tilley BD, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Intern Med 1995;122:81-9.
14. 14. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellava B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non Q wave coronary syndrome. The final report of the ROXIS study. Eur Heart J 1999;20:89-92.
15. 15. Grayston JT. Antibiotic treatment trials for secondary prevention of coronary artery disease events. Circulation 1999;99:1538-9.